18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WA
Investor Presentation
LeonaBio, Inc. Approves 2026 Equity Incentive Plan at Special Meeting
Announces Name Change to LeonaBio, Inc. with New Ticker 'LONA'
Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million, Investor Presentation
Amended material disclosure
Earnings Release
Other Events
Announces Reverse Stock Split
FY 2025
Q3
Q2
Q1
FY 2023
Q2 amended
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Amended Registration Statement for Securities
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Definitive Revised Proxy Statement
Submission Upload
Correspondence